Most Read Articles
Audrey Abella, 24 Jul 2020
Two phase III trials have shown that reducing serum urate (SU) levels with allopurinol did not provide a clinically meaningful benefit in individuals with kidney disease.
Elvira Manzano, 01 Jul 2020
Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.
Roshini Claire Anthony, 19 Jun 2019

A daily dose of atrasentan added to renin-angiotensin system inhibitors may slow the progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), results from the SONAR* trial showed.

Product Highlight - Rexulti

4 days ago

REXULTI® (Brexpiprazole) Tablet is an Atypical Antipsychotic as a “Serotonin-Dopamine Activity Modulator” (SDAM) that combines partial agonist activity at serotonin 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors (Ki: 0.1 nM to 0.5 nM).

Brexpiprazole also shows antagonist activity at noradrenergic α1B/2C receptors with affinity in the same sub-nanomolar Ki range (Ki: 0.2 nM to 0.6 nM).

Indication:
Adjunctive treatment for major depressive disorder (MDD) in adult
Treatment of schizophrenia in adult

Dosage and Administration: Schizophrenia:
Starting dose: 1 mg once daily on days 1-4. Recommended dose: 2-4 mg once daily (Be titrated to 2 mg once daily on day 5 through day 7 and then to 4 mg on day 8). Maximum daily dose: 4 mg.

MDD:
Starting dose: 0.5 mg or 1 mg once daily. Recommended dose: 2 mg once daily (Dosage increases should occur at weekly intervals). Maximum daily dose: 3 mg.



Reference: Prescribing Information of REXULTI

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 24 Jul 2020
Two phase III trials have shown that reducing serum urate (SU) levels with allopurinol did not provide a clinically meaningful benefit in individuals with kidney disease.
Elvira Manzano, 01 Jul 2020
Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.
Roshini Claire Anthony, 19 Jun 2019

A daily dose of atrasentan added to renin-angiotensin system inhibitors may slow the progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), results from the SONAR* trial showed.